Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency

Clinical and Experimental Immunology

Volumn 181, Issue 3, 2015, Pages 441-450

  Niebur, H B ^a   Duff, C M ^a   Shear, G F ^a   Nguyen, D ^a   Alberdi, T K ^a   Dorsey, M J ^a   Sleasman, J W ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Antibody deficiency; Hizentra; IgG; Immunodeficiency; IVIG; Pneumococcal titres; Quality of life; Subcutaneous immunoglobulin; Varicella; Vivaglobin

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; APPLICATION SITE EDEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTHRALGIA; ARTICLE; BACTERIAL LOAD; CHICKENPOX; CHILD; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; MALAISE; MALE; OPEN STUDY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRIMARY ANTIBODY DEFICIENCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TETANUS; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; EDEMA; FEVER; HEADACHE; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; FEVER; HEADACHE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939258432     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12623     Document Type: Article

References (41)

1. Bonilla FA, Bernstein IL, Khan DA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S1-63.
2. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525-53.
3. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:413-37.
4. (R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011; 141:90-102.
5. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112:1-7.
6. Borte M, Bernatowska E, Ochs HD, Roifman CM. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin.Exp Immunol 2011; 164:357-64.
7. Gardulf A, Nicolay U, Math D et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-42.
8. Gardulf A, Borte M, Ochs HD, Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126:81-8.
9. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265-73.
10. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010; 103:856-63.
11. Anderson D, Caspi A. Hizentra immune globulin subcutaneous (human), 20% liquid. P&T Product Profiler 2010; 35:1-22.
12. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139:133-41.
13. Hagan JB, Fasano MB, Spector S et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734-45.
14. Al-Herz W, Bousfiha A, Casanova JL et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies expert committee for primary immunodeficiency. Front Immunol 2014; 5:1-33
15. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency 2008. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm078526.pdf (accessed 14 November 2012)
16. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8 (Suppl. 1):S9-S24.
17. Trujols J, Iraurgi I, Sinol N, Portella MJ, Perez V, Perez de Los Cobos J. Satisfaction with methadone as a medication: psychometric properties of the Spanish version of the treatment satisfaction questionnaire for medication. J Clin Psychopharmacol 2012; 32:69-74.
18. Tetanus Epidemiology and Prevention of Vaccine-Preventable Diseases. The pink book: course textbook, 12th edn. Centers for Disease Control and Prevention website: The Public Health Foundation, 2012:291-300.
19. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56:1-40.
20. Siber GR, Chang I, Baker S et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816-3826.
21. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 2008; 101:114-21; quiz 22-3, 78.
22. Wasserman RL, Melamed I, Nelson RP Jr et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011; 50:405-14.
23. Subcutaneous immune globulin (SCIG). Med Lett Drugs Ther 2007; 49:31-2.
24. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:90-7.
25. Berger M, Jolles S, Orange JS, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol 2013; 33:984-90.
26. Orange JS, Belohradsky BH, Berger M et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.Clin Exp Immunol 2012; 169:172-81
27. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:21-30.
28. Shehab Z, Brunell PA. Enzyme-linked immunosorbent assay for susceptibility to varicella. J Infect Dis 1983; 148:472-6.
29. Webb NJ, Fitzpatrick MM, Hughes DA et al. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000; 82:141-3.
30. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, Tangsinmankong N. Validation of current joint American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol 2006; 118:1336-41.
31. Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol 2007; 99:462-4.
32. Musher DM, Manof SB, Liss C et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516-24.
33. Maeder W, Lieby P, Sebald A, Spycher M, Pedrussio R, Bolli R. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals 2011; 39:43-9.
34. Immune Globulin Subcutaneous (Human) Vivaglobin: for the treatment of primary immunodeficiency diseases. P&T Product Profiler 2009; 34:2-21.
35. Bolli R, Woodtli K, Bartschi M, Hofferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 2010; 38:150-7.
36. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28:803-19, ix.
37. Stein MR, Nelson RP, Church JA et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 2009; 29:137-44.
38. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122:1238-9.
39. Sweileh WM, Ihbesheh MS, Jarar IS et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 2011; 21:301-5.
40. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:65-72.
41. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:434-42.